Ardelyx (ARDX) Stock Price, News & Analysis

Company Overview

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $3.81 to $4.00
• 50-Day Range: $3.73 to $5.62
• 52-Week Range: $3.62 to $9.33
• Volume: 8.92 million shs
• Average Volume: 4.38 million shs
• Market Capitalization: $945.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.39
• Consensus Rating: Moderate Buy

Ardelyx Stock Analysis - MarketRank™

Ardelyx scored higher than 89% of companies evaluated by MarketBeat, and ranked 150th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Ardelyx has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Ardelyx has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ardelyx are expected to grow in the coming year, from ($0.18) to $0.31 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ardelyx is -24.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ardelyx is -24.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ardelyx has a P/B Ratio of 5.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.55% of the float of Ardelyx has been sold short.

Short Interest Ratio / Days to Cover

Ardelyx has a short interest ratio ("days to cover") of 7.

Change versus previous month

Short interest in Ardelyx has recently decreased by 1.47%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ardelyx does not currently pay a dividend.

Dividend Growth

Ardelyx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.32

Percentage of Shares Shorted

13.55% of the float of Ardelyx has been sold short.

Short Interest Ratio / Days to Cover

Ardelyx has a short interest ratio ("days to cover") of 7.

Change versus previous month

Short interest in Ardelyx has recently decreased by 1.47%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.12

News Sentiment

Ardelyx has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 33 news articles for Ardelyx this week, compared to 9 articles on an average week.

Search Interest

Only 5 people have searched for ARDX on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.

MarketBeat Follows

12 people have added Ardelyx to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Ardelyx insiders have bought 156.97% more of their company's stock than they have sold. Specifically, they have bought $1,998,056.00 in company stock and sold $777,555.00 in company stock.

Percentage Held by Insiders

Only 5.90% of the stock of Ardelyx is held by insiders.

Percentage Held by Institutions

58.92% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ARDX Stock Analysis - Frequently Asked Questions

How have ARDX shares performed this year?

Ardelyx's stock was trading at $5.07 on January 1st, 2025. Since then, ARDX shares have decreased by 21.8% and is now trading at $3.9650.
View the best growth stocks for 2025 here.

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) announced its quarterly earnings data on Thursday, May, 1st. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.07. The firm's revenue was up 61.1% compared to the same quarter last year.

Who are Ardelyx's major shareholders?

Ardelyx's top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.35%), Bank of New York Mellon Corp (0.30%), Palisades Investment Partners LLC (0.22%) and Pekin Hardy Strauss Inc. (0.19%). Insiders that own company stock include David M Mott, Michael Raab, Susan Rodriguez, Robert Blanks, Elizabeth A Grammer, Laura A Williams, Justin A Renz, David P Rosenbaum and Robert Ora Felsch.
View institutional ownership trends.

How do I buy shares of Ardelyx?

Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ardelyx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ardelyx investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), e.l.f. Beauty (ELF), GE Aerospace (GE), Builders FirstSource (BLDR) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARDX
• CIK: 1437402
• Web: www.ardelyx.com
• Phone: (510) 745-1700
• Fax: 510-745-0493
• Employees: 90
• Year Founded: 2007

Price Target and Rating

• Average Stock Price Target: $10.39
• High Stock Price Target: $15.00
• Low Stock Price Target: $5.50
• Potential Upside/Downside: +162.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-39,140,000.00
• Net Margins: -11.73%
• Pretax Margin: -11.65%
• Return on Equity: -24.87%
• Return on Assets: -10.51%

Debt

• Debt-to-Equity Ratio: 0.87
• Current Ratio: 4.58
• Quick Ratio: 4.31

Sales & Book Value

• Annual Sales: $333.62 million
• Price / Sales: 2.83
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.73 per share
• Price / Book: 5.43

Miscellaneous

• Outstanding Shares: 238,356,000
• Free Float: 222,880,000
• Market Cap: $945.08 million
• Optionable: Optionable
• Beta: 0.76